

INVESTIGATOR LETTER

Date: November 16, 2020

To: **S1900A** Participating Investigators

RE: Permanent Closure to Accrual for **S1900A** Cohort 1 (Squamous Cell Lung Cancer)

S1900A: "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)"

S1900A Cohort 1 (squamous cell lung cancer) was permanently closed to accrual on November 16, 2020 as the study met prespecified futility threshold at the planned interim analysis.

Patients with squamous cell lung cancer currently receiving treatment on **S1900A** must be notified that the study team reviewed patient data to date and did not find that rucaparib was sufficiently active to continue enrolling patients to Cohort 1. The manner by which this notification should take place is at the discretion of the local Institutional Review Board (IRB). At a minimum, patients with squamous cell lung cancer in Cohort 1 currently receiving the experimental therapy (rucaparib) must be notified of the results of the interim analysis. The attached "Patient Information Letter" may be used if desired.

Patients with squamous cell lung cancer in Cohort 1 currently receiving treatment on **S1900A** may continue treatment with rucaparib at the discretion of the treating physician if the patient is deriving clinical benefit, agrees to continue treatment, and if their physician feels that it is in the patient's best interest to continue treatment at this time.

It is recommended that the patient be notified as soon as possible to make the determination of whether to continue treatment.

Sites are expected to continue the protocol-specified data submission requirements in Section 14.0 for all patients.

Continued follow-up and reporting of adverse events, progression and survival is important to all subsequent analyses of this trial. Therefore, we strongly encourage all investigators to continue to submit follow-up forms on this trial. We also request that any outstanding forms be completed and submitted as soon as possible.

Please direct questions to:

Eligibility/Data Submissions: LungmapQuestion@crab.org

S1900A Treatment-related/Medical: S1900AMedicalQuery@swog.org

Protocol/Regulatory: mnorman@swog.org

Thank you for your continued participation in the Lung-MAP trial.

Sincerely,

Roy Herbst, M.D., Ph.D.
Mary Redman, Ph.D.

Jonathan W. Riess, M.D.
Paul Wheatley-Price, M.D.